ObsEva

ObsEva is a Swiss-based company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva´s lead product is a clinical stage compound licensed from Merck Serono.

http://www.obseva.com

Team Member
more about
Jasper Bos
Latest News Entry
2017/06/29
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
  • Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART
  • Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential
2017/06/07
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the completion of a Phase 1 clinical trial aimed at evaluating the PK/PD relationship of OBE2109 combined with different doses of add-back therapy.

2017/05/11
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017

Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017.

2017/03/24
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

2017/03/17
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
  • OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist -
2017/03/07
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
  • IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer as part of assisted reproductive technology (ART) -
2017/01/26
ObsEva SA Announces Pricing of Initial Public Offering

Geneva, Switzerland - January 25, 2017 - ObsEva SA (ObsEva) announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "OBSV" on January 26, 2017.

Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the proposed offering.

2017/01/17
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans

Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman’s reproductive health and pregnancy, announced today the appointment of a new Chief Financial Officer, Timothy M. Adams. Mr. Adams will be located in the Company’s U.S. headquarters in Boston, Massachusetts, which is expected to employ finance, IR and clinical operation people and support ObsEva’s clinical-stage programs in uterine fibroids, endometriosis, Assisted Reproductive Technology and preterm labor.

2017/01/13
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

  • First-in-class orally active prostaglandin F2alpha receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that can result in preterm birth -

Geneva, Switzerland, 13 January 2017 - ObsEva, a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman's reproductive health and pregnancy, announced today the completion of a Phase 1 single and multiple ascending dose study of OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha, or PGF2alpha, receptor antagonist for the treatment of preterm labor in weeks 24 to 34 of pregnancy. ObsEva is developing OBE022 to safely control PGF2alpha-mediated inflammation, decreasing uterine contractions and preventing membrane ruptures and cervical changes, which are the key features of preterm labor resulting in preterm birth. The study evaluated the safety, tolerability and pharmacokinetics of OBE022 in healthy post-menopausal female volunteers after single doses of 10 to 1,300 mg and multiple doses between 100 and 1,000 mg/day over 7 consecutive days.

2016/10/17
ObsEva Announces Plans to Conduct Initial Public Offering in the United States

GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the Company plans to conduct an initial public offering in the United States.

2016/10/12
ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis

GENEVA, SWITZERLAND, 12 October, 2016 - ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced randomization of the first patient in its Phase 2b clinical study (EDELWEISS) of OBE2109 for the treatment of endometriosis. OBE2109 is a novel, orally administered, gonadotropin-releasing hormone (GnRH) antagonist that has been tested in more than 150 Japanese patients with endometriosis. In those Phase 2a studies, conducted by Kissei Pharmaceutical Co., Ltd. (Kissei), a dose-dependent suppression of estradiol was observed with treatment with OBE2109. In addition, patients reported significant reductions of endometriosis-associated pelvic pain, analgesic use and bleeding days.

2015/11/23
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

Obseva announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing. The financing included new investors HBM Healthcare Investments, New Enterprise

2015/02/26
ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour

Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from ...

1970/01/01
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI

Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001
ObsEva to proceed with a Phase 3 clinical trial in Europe

Geneva, Switzerland, 24 October 2016 - ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman's reproductive health and pregnancy, announced today the results of its IMPLANT clinical trial, a Phase 2 clinical trial of OBE001 (nolasiban) for the improvement of clinical pregnancy and live birth rates in women undergoing embryo transfer (ET) following in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The trial was designed to assess the safety and efficacy of a range of doses of OBE001, an oral oxytocin receptor antagonist, compared to placebo.

all related news
all portfolio news